Drug intelligence / Profile preview

plasmid GDNF DNA

Development stage: Preclinical
Lead developer: Northeastern University
Modality: Gene Therapies, Nanoparticles → Drug Delivery Systems
Administration: Intranasal

Overview

The drug 'plasmid GDNF DNA' is a gene therapy under development by Northeastern University in collaboration with Copernicus Therapeutics and Tufts University, supported by a grant from the National Institute on Drug Abuse (NIDA) through the NIH HEAL Initiative. This therapy employs Copernicus's patented, non-viral DNA nanoparticles (pGDNF NPs) for the intranasal delivery of the Glial cell line-derived neurotrophic factor (GDNF) gene to the brain. The primary objective is to restore dopamine function and mitigate drug-seeking behavior, specifically targeting opioid use disorder.

Targets

GFRA1 (Glial cell line-derived neurotrophic factor family receptor alpha 1)

Beyond the preview

Go deeper on plasmid GDNF DNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on plasmid GDNF DNA.

Explore the full profile